Abstract
Among the novel biologic therapeutics that will increase our ability to cure human cancer in the years to come, T cell therapy is one of the most promising approaches. However, with the possible exception of tumor-infiltrating lymphocytes therapy for melanoma, clinical trials of adoptive T-cell therapy for solid tumors have so far provided only clear proofs-of-principle to build on with further development. Epstein-Barr virus (EBV)-associated malignancies offer a unique model to develop T cell-based immune therapies, targeting viral antigens expressed on tumor cells. In the last two decades, EBV-specific cytotoxic T-lymphocytes (CTL) have been successfully employed for the prophylaxis and treatment of EBV-related lymphoproliferative disorders in immuno-compromised hosts. More recently, this therapeutic approach has been applied to the setting of EBV-related solid tumors, such as nasopharyngeal carcinoma. The results are encouraging, although further improvements to the clinical protocols are clearly neces-sary to increase anti-tumor activity. Promising implementations are underway, including harnessing the therapeutic potential of CTLs specific for subdominant EBV latent cycle epitopes, and delineating strategies aimed at targeting immune evasion mechanisms ex-erted by tumor cells.
| Original language | English |
|---|---|
| Pages (from-to) | 341-346 |
| Number of pages | 6 |
| Journal | Journal of Cancer |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2011 |
Fingerprint
Keywords
- Cytotoxic T lymphocytes
- Epstein-Barr virus
- Nasopharyngeal carcinoma
- T-cell therapy
ASJC Scopus subject areas
- Oncology
Cite this
T cell therapy for nasopharyngeal carcinoma. / Basso, S.; Zecca, M.; Merli, P.; Gurrado, A.; Secondino, S.; Quartuccio, G.; Guido, I.; Guerini, P.; Ottonello, G.; Zavras, N.; Maccario, R.; Pedrazzoli, P.; Comoli, P.
In: Journal of Cancer, Vol. 2, No. 1, 2011, p. 341-346.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - T cell therapy for nasopharyngeal carcinoma
AU - Basso, S.
AU - Zecca, M.
AU - Merli, P.
AU - Gurrado, A.
AU - Secondino, S.
AU - Quartuccio, G.
AU - Guido, I.
AU - Guerini, P.
AU - Ottonello, G.
AU - Zavras, N.
AU - Maccario, R.
AU - Pedrazzoli, P.
AU - Comoli, P.
PY - 2011
Y1 - 2011
N2 - Among the novel biologic therapeutics that will increase our ability to cure human cancer in the years to come, T cell therapy is one of the most promising approaches. However, with the possible exception of tumor-infiltrating lymphocytes therapy for melanoma, clinical trials of adoptive T-cell therapy for solid tumors have so far provided only clear proofs-of-principle to build on with further development. Epstein-Barr virus (EBV)-associated malignancies offer a unique model to develop T cell-based immune therapies, targeting viral antigens expressed on tumor cells. In the last two decades, EBV-specific cytotoxic T-lymphocytes (CTL) have been successfully employed for the prophylaxis and treatment of EBV-related lymphoproliferative disorders in immuno-compromised hosts. More recently, this therapeutic approach has been applied to the setting of EBV-related solid tumors, such as nasopharyngeal carcinoma. The results are encouraging, although further improvements to the clinical protocols are clearly neces-sary to increase anti-tumor activity. Promising implementations are underway, including harnessing the therapeutic potential of CTLs specific for subdominant EBV latent cycle epitopes, and delineating strategies aimed at targeting immune evasion mechanisms ex-erted by tumor cells.
AB - Among the novel biologic therapeutics that will increase our ability to cure human cancer in the years to come, T cell therapy is one of the most promising approaches. However, with the possible exception of tumor-infiltrating lymphocytes therapy for melanoma, clinical trials of adoptive T-cell therapy for solid tumors have so far provided only clear proofs-of-principle to build on with further development. Epstein-Barr virus (EBV)-associated malignancies offer a unique model to develop T cell-based immune therapies, targeting viral antigens expressed on tumor cells. In the last two decades, EBV-specific cytotoxic T-lymphocytes (CTL) have been successfully employed for the prophylaxis and treatment of EBV-related lymphoproliferative disorders in immuno-compromised hosts. More recently, this therapeutic approach has been applied to the setting of EBV-related solid tumors, such as nasopharyngeal carcinoma. The results are encouraging, although further improvements to the clinical protocols are clearly neces-sary to increase anti-tumor activity. Promising implementations are underway, including harnessing the therapeutic potential of CTLs specific for subdominant EBV latent cycle epitopes, and delineating strategies aimed at targeting immune evasion mechanisms ex-erted by tumor cells.
KW - Cytotoxic T lymphocytes
KW - Epstein-Barr virus
KW - Nasopharyngeal carcinoma
KW - T-cell therapy
UR - http://www.scopus.com/inward/record.url?scp=84856506061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856506061&partnerID=8YFLogxK
U2 - 10.7150/jca.2.341
DO - 10.7150/jca.2.341
M3 - Article
AN - SCOPUS:84856506061
VL - 2
SP - 341
EP - 346
JO - Journal of Cancer
JF - Journal of Cancer
SN - 1837-9664
IS - 1
ER -